MTL CEBPA

Drug Profile

MTL CEBPA

Alternative Names: MTL-CEBPA

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer MiNA Therapeutics
  • Class Antineoplastics; Oligonucleotides; RNA
  • Mechanism of Action RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Liver cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 14 Nov 2016 Updated pharmacodynamics data from preclinical study in Pancreatic cancer released by MiNA Therapeutics
  • 11 Nov 2016 Updated pharmacodynamics data from a preclinical study in Liver cancer presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AALD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top